Abstract
Alzheimer’s disease (AD) is a complex and progressive neurodegenerative disorder, and represents the most common form of dementia. The number of people affected by AD is estimated to be doubled by the year of 2050, and more than 100 million people worldwide will be affected by this disease. Still, there is no reliable diagnostic test which would indicate pre-symptomatic conditions or an increased risk of developing AD. The only drugs approved by the FDA belong to the cholinesterase inhibitors (ChEI) group, such as donepezil, rivastigmine, galantamine and memantine that belongs to a class of drugs named receptor NMDA antagonists. Most mainstream pharmacotherapeutic approaches act by slowing the progression of the condition rather than to treat or prevent the cause of AD. In this review we are presenting literature data from recent research related to new avenues in the classical approach to prevention and treatment of AD.
Keywords: Aβ, Alzheimer’s disease, cholinesterase inhibitors, hybrids, memantine, neurodegeneration.
Current Pharmaceutical Analysis
Title:Treatment of Alzheimer's Disease: Classical Therapeutic Approach
Volume: 12 Issue: 2
Author(s): Vladan Bajic, Emina Sudar Milovanovic, Biljana Spremo-Potparevic, Lada Zivkovic, Zorka Milicevic, Julijana Stanimirovic, Nikola Bogdanovic and Esma R. Isenovic
Affiliation:
Keywords: Aβ, Alzheimer’s disease, cholinesterase inhibitors, hybrids, memantine, neurodegeneration.
Abstract: Alzheimer’s disease (AD) is a complex and progressive neurodegenerative disorder, and represents the most common form of dementia. The number of people affected by AD is estimated to be doubled by the year of 2050, and more than 100 million people worldwide will be affected by this disease. Still, there is no reliable diagnostic test which would indicate pre-symptomatic conditions or an increased risk of developing AD. The only drugs approved by the FDA belong to the cholinesterase inhibitors (ChEI) group, such as donepezil, rivastigmine, galantamine and memantine that belongs to a class of drugs named receptor NMDA antagonists. Most mainstream pharmacotherapeutic approaches act by slowing the progression of the condition rather than to treat or prevent the cause of AD. In this review we are presenting literature data from recent research related to new avenues in the classical approach to prevention and treatment of AD.
Export Options
About this article
Cite this article as:
Bajic Vladan, Milovanovic Sudar Emina, Spremo-Potparevic Biljana, Zivkovic Lada, Milicevic Zorka, Stanimirovic Julijana, Bogdanovic Nikola and Isenovic R. Esma, Treatment of Alzheimer's Disease: Classical Therapeutic Approach, Current Pharmaceutical Analysis 2016; 12 (2) . https://dx.doi.org/10.2174/1573412911666150611184740
DOI https://dx.doi.org/10.2174/1573412911666150611184740 |
Print ISSN 1573-4129 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-676X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Neuroprotective Properties of Standardized Extracts of Hypericum perforatum on Rotenone Model of Parkinson’s Disease
CNS & Neurological Disorders - Drug Targets Calcitonin-Derived Carrier Peptides
Current Pharmaceutical Design Pathophysiology and Treatment of Diabetic Peripheral Neuropathy: The Case for Diabetic Neurovascular Function as an Essential Component
Current Diabetes Reviews New Molecular Avenues in Parkinson ’ s Disease Therapy
Current Topics in Medicinal Chemistry p35 Deficiency Accelerates HMGB-1-mediated Neuronal Death in the Early Stages of an Alzheimer's disease Mouse Model
Current Alzheimer Research The Ubiquitin-Proteasome System (UPS) and the Mechanism of Action of Bortezomib
Current Pharmaceutical Design Metastasis-Inducing S100A4 Protein: Implication in Non-Malignant Human Pathologies
Current Molecular Medicine Prodrug Design of Phenolic Drugs
Current Pharmaceutical Design Increased Aβ1-42 Production Sensitizes Neuroblastoma Cells for ER Stress Toxicity
Current Alzheimer Research Dendrimers as Novel Systems for Delivery of Neuropharmaceuticals to the Brain
CNS & Neurological Disorders - Drug Targets P2X7 Receptors: Channels, Pores and More
CNS & Neurological Disorders - Drug Targets Superparamagnetic Magnetite (Fe3O4) Nanoparticles for Bio-Applications
Recent Patents on Materials Science Tumor Biomarkers: Clinical Utility, Promises and Problems
Applied Clinical Research, Clinical Trials and Regulatory Affairs Synthesis of the Alzheimer Drug Posiphen into its Primary Metabolic Products (+)-N1-norPosiphen, (+)-N8-norPosiphen and (+)-N1, N8-bisnorPosiphen, their Inhibition of Amyloid Precursor Protein, α -Synuclein Synthesis, Interleukin-1β Release, and Cholinergic Action.
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Nanomedicine against Alzheimer’s and Parkinson’s Disease
Current Pharmaceutical Design Neurotrophic Actions of Mood-Stabilizers: A Recent Research Discovery and its Potential Clinical Applications
Current Psychiatry Reviews Membrane Domains and the “Lipid Raft” Concept
Current Medicinal Chemistry Glucocorticoid Regulates Parkin Expression in Mouse Frontal Cortex: Implications in Schizophrenia
Current Neuropharmacology Overview of microRNA Target Analysis Tools
Current Bioinformatics Synthetic Lipoproteins as Carriers for Drug Delivery
Current Medicinal Chemistry